425 related articles for article (PubMed ID: 15094157)
1. Tyrosine kinase receptors as attractive targets of cancer therapy.
Bennasroune A; Gardin A; Aunis D; Crémel G; Hubert P
Crit Rev Oncol Hematol; 2004 Apr; 50(1):23-38. PubMed ID: 15094157
[TBL] [Abstract][Full Text] [Related]
2. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
3. Receptor tyrosine kinases as targets for anticancer drugs.
Zwick E; Bange J; Ullrich A
Trends Mol Med; 2002 Jan; 8(1):17-23. PubMed ID: 11796262
[TBL] [Abstract][Full Text] [Related]
4. Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases.
Abella JV; Park M
Am J Physiol Endocrinol Metab; 2009 May; 296(5):E973-84. PubMed ID: 19240253
[TBL] [Abstract][Full Text] [Related]
5. Monitoring interactions between receptor tyrosine kinases and their downstream effector proteins in living cells using bioluminescence resonance energy transfer.
Tan PK; Wang J; Littler PL; Wong KK; Sweetnam TA; Keefe W; Nash NR; Reding EC; Piu F; Brann MR; Schiffer HH
Mol Pharmacol; 2007 Dec; 72(6):1440-6. PubMed ID: 17715395
[TBL] [Abstract][Full Text] [Related]
6. Receptor tyrosine kinase inhibitors as anti-angiogenic agents.
Kim DW; Lu B; Hallahan DE
Curr Opin Investig Drugs; 2004 Jun; 5(6):597-604. PubMed ID: 15242247
[TBL] [Abstract][Full Text] [Related]
7. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.
Doepfner KT; Boller D; Arcaro A
Crit Rev Oncol Hematol; 2007 Sep; 63(3):215-30. PubMed ID: 17658267
[TBL] [Abstract][Full Text] [Related]
8. A functional RNAi screen for regulators of receptor tyrosine kinase and ERK signalling.
Friedman A; Perrimon N
Nature; 2006 Nov; 444(7116):230-4. PubMed ID: 17086199
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment.
Roussidis AE; Karamanos NK
In Vivo; 2002; 16(6):459-69. PubMed ID: 12494890
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical progress.
Renhowe PA
Curr Opin Drug Discov Devel; 2002 Mar; 5(2):214-24. PubMed ID: 11926128
[TBL] [Abstract][Full Text] [Related]
11. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
Broxterman HJ; Georgopapadakou NH
Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
[TBL] [Abstract][Full Text] [Related]
12. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
[TBL] [Abstract][Full Text] [Related]
13. Receptor tyrosine kinases: from biology to pathology.
Choura M; Rebaï A
J Recept Signal Transduct Res; 2011 Dec; 31(6):387-94. PubMed ID: 22040163
[TBL] [Abstract][Full Text] [Related]
14. The ErbB/HER receptor protein-tyrosine kinases and cancer.
Roskoski R
Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
[TBL] [Abstract][Full Text] [Related]
15. Integrating signals from RTKs to ERK/MAPK.
McKay MM; Morrison DK
Oncogene; 2007 May; 26(22):3113-21. PubMed ID: 17496910
[TBL] [Abstract][Full Text] [Related]
16. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium.
Fuller SJ; Sivarajah K; Sugden PH
J Mol Cell Cardiol; 2008 May; 44(5):831-54. PubMed ID: 18430438
[TBL] [Abstract][Full Text] [Related]
17. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
18. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.
Matsumura I; Mizuki M; Kanakura Y
Cancer Sci; 2008 Mar; 99(3):479-85. PubMed ID: 18177485
[TBL] [Abstract][Full Text] [Related]
19. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?
Fischer B; Marinov M; Arcaro A
Cancer Treat Rev; 2007 Jun; 33(4):391-406. PubMed ID: 17368733
[TBL] [Abstract][Full Text] [Related]
20. Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function.
Mukherjee S; Tessema M; Wandinger-Ness A
Circ Res; 2006 Mar; 98(6):743-56. PubMed ID: 16574915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
